FOLFOXIRI Combined With Cetuximab as a Neoadjuvant Chemotherapy for EGFR Wild Type Locally Advanced Rectal Cancer:A Phase II Study
Overview
- Phase
- Phase 2
- Intervention
- FOLFOXIRI+Cetuximab regimen
- Conditions
- Rectal Cancer Stage III
- Sponsor
- RenJi Hospital
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Pelvic complete resection rate
- Status
- Active, not recruiting
- Last Updated
- 8 years ago
Overview
Brief Summary
A number of pilot studies had shown high rate of complete resection after neoadjuvant chemotherapy alone for local advanced rectal cancer(LARC), but they did not increase the ratio of pathological complete response (pCR) which was associated with improvement of overall survival (OS). On the other hand,some clinical trials show that triple active cytotoxic agents (Fluorouracil, Oxaliplatin, Irinotecan, FOLFOXIRI) combined with cetuximab for EGFR wild type metastatic colorectal cancer had more effective than double agents.Therefore,a hypothesis is the FOLFOXIRI+Cetuximab as the neoadjuvant chemotherapy regimen might improve the patient's ratio of pCR.
Detailed Description
This is a multicenter, phase II trial to assess the efficacy and safety of triplet regimen (FOLFOXIRI) combined with cetuximab for patients with EGFR wild type LARC. After 4 cycles of FOLFOXIRI+cetuximab and 2 weeks later, the patients will be evaluated by senior radiologist, oncologist and surgeon through pelvic MRI, CT and Positron Emission Computed Tomography (PET-CT). The patients will go to surgery (TME) if the tumor response is good enough to have complete resection under the decision of the multidisciplinary team (MDT),otherwise, the patients will receive pelvic radiotherapy(45Grey/25Fraction and 5.4Grey/3Fraction boost to the tumor bed) combined with capecitabine(625 mg/m²,bid po,d1-5,qw), and additional four cycles of modified FOLFOX6 (mFOLFOX6) or Oxaliplatin 135mg/m²plus Capecitabine 1.0/m², bid po(XELOX) of each 3 weeks cycle for 2 cycles chemotherapy before TME. All patients will receive 6-8 cycles of mFOLFOX6 or 4-5 cycles XELOX as adjuvant chemotherapy after TME. FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h + Cetuximab 500 mg/m²,all on day 1 of each 2 weeks cycle for 4-6 cycles, Other Names: CPT11，CAMPTO Eloxatin Xelod Erbitux
Investigators
Yeming
Renji Hospital
RenJi Hospital
Eligibility Criteria
Inclusion Criteria
- •Age ≥ 18 to 75 years at diagnosis
- •Diagnosis of rectal adenocarcinoma
- •ECOG status: 0～1
- •Clinical stage II (T3-4, N0) or stage III (T1-4, N1-2)
- •Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment:
- •,Leukocytes ≥ 3.0 x109/ L, 2),Absolute neutrophil count (ANC) ≥ 1.5 x109/ L 3),Platelet count ≥ 100 x109/ L, 4),Hemoglobin (Hb) ≥ 9g/ dL. 5),Total bilirubin ≤1.5 x the upper limit of normal (ULN). 6),Alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) ≤ 3 x ULN. 7),Serum creatinine ≤ 1.5 x the ULN. 8),Signed informed consent;
Exclusion Criteria
- •Patient had received pelvic radiotherapy;
- •Patient had received systemic chemotherapy
- •Pregnant and Nursing women
- •Had metastatic disease
- •Uncontrolled co-morbid illnesses or other concurrent disease
- •Patient had second malignant disease within 5 years
- •Patients refused to signed informed consent.
Arms & Interventions
FOLFOXIRI+Cetuximab
FOLFOXIRI+Cetuximab regimen:Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h and cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle for 4-6 cycles.
Intervention: FOLFOXIRI+Cetuximab regimen
Outcomes
Primary Outcomes
Pelvic complete resection rate
Time Frame: Up to 10 weeks
Pathologic confirmation
Secondary Outcomes
- The rate of clinical complete response after 4 cycles of FOLFOXIRI(Up to 10 weeks)
- Overall survival(Three years)
- The rate of receive chemoradiation(Up to 10 weeks)
- The rate of local control(3 years)
- Disease free survival (DFS)(Three years)
- The incidence of >=3 grade adverse events(Two years)